Advertisement
Grab your lab coat. Let's get started
Welcome!
Welcome!
Create an account below to get 6 C&EN articles per month, receive newsletters and more - all free.
It seems this is your first time logging in online. Please enter the following information to continue.
As an ACS member you automatically get access to this site. All we need is few more details to create your reading experience.
Not you? Sign in with a different account.
Not you? Sign in with a different account.
ERROR 1
ERROR 1
ERROR 2
ERROR 2
ERROR 2
ERROR 2
ERROR 2
Password and Confirm password must match.
If you have an ACS member number, please enter it here so we can link this account to your membership. (optional)
ERROR 2
ACS values your privacy. By submitting your information, you are gaining access to C&EN and subscribing to our weekly newsletter. We use the information you provide to make your reading experience better, and we will never sell your data to third party members.
Credit: Rianne Lord
Although at first glance it may look like a French custard dessert, this is actually a photo of a vial containing a functionalized β-diketonate ligand after recrystallization. The ligand was made by Imogen Turner, an undergraduate student in Rianne Lord’s research group at the University of East Anglia. The team’s research goal is to design vanadium complexes that will be more active and selective for treating cancer than current platinum-based drugs, and then study how the complexes affect cancer cells versus healthy cells. Lord leads the project, runs crystallography for the team, and will occasionally share photos of the crystals on social media.
Credit: Rianne Lord. Follow her on Twitter @DrRianneLord and her group @lord_research.
Do science. Take pictures. Win money. Enter our photo contest here.
UPDATE
This story was updated on May 27, 2022 to include the student's name.
Chemical & Engineering News
ISSN 0009-2347
Copyright © 2023 American Chemical Society
You might also like...
The power is now in your (nitrile gloved) hands
Sign up for a free account to get more articles. Or choose the ACS option that’s right for you.
Already have an ACS ID? Log in
Join the conversation
Contact the reporter
Submit a Letter to the Editor for publication
Engage with us on Twitter